Pfenex Inc.

2:30 PM - 2:45 PM, Tuesday, June 4, 2019 ・ Theater 2
We are a clinical-stage development and licensing biotechnology company focused on leveraging our Pfēnex Expression Technology®to develop and improve protein therapies for unmet patient needs.
Ticker:
PFNX
Exchange:
NYSE - American
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Lead Product in Development:
PF708 - Teriparatide
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
Chief Business Officer
Pfenex Inc.